Methoxyamine hydrochloride - TRACON Pharmaceuticals
Alternative Names: Methoxyamine - TRACON; TRC 102Latest Information Update: 24 Mar 2025
At a glance
- Originator Case Western Reserve University
- Developer Case Western Reserve University; National Cancer Institute (USA); TRACON Pharmaceuticals
- Class Antineoplastics; Hydroxylamines; Small molecules
- Mechanism of Action DNA repair inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma; Haematological malignancies; Lymphoma; Mesothelioma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 12 Nov 2024 Discontinued - Phase-I for Haematological malignancies (Combination therapy, Second-line therapy or greater) in USA (IV) (TRACON Pharmaceuticals website, March 2025)
- 12 Nov 2024 Discontinued - Phase-I for Lymphoma (Second-line therapy or greater, Combination therapy) in USA (PO) (TRACON Pharmaceuticals website, March 2025)
- 12 Nov 2024 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Late-stage disease) in USA (PO) (TRACON Pharmaceuticals website, March 2025)